Breast Cancer

Breast CancerSan Antonio 2022

Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

9 December 2022

Tucatinib is an oral HER2-targeted therapy that was approved by the FDA in...

Breast CancerSan Antonio 2022

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

8 December 2022

One year of adjuvant trastuzumab with 12 cycles of weekly paclitaxel represents...

Breast CancerSan Antonio 2022

Challenging the current 1-10% cut-off for defining Estrogen Receptor (ER) Low Positive grade 2-3 ER positive, HER2- early breast cancer

8 December 2022

The 2020 ASCO-CAP guidelines recommended ER Low Positive as new reporting...

Breast CancerSan Antonio 2022

Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score.

7 December 2022

Dr. Vangoitsenhoven from KU Leuven evaluated how the adjuvant endocrine therapy...

Breast CancerSan Antonio 2022

Post-NET KI-67 index is a valuable prognostic biomarker in women with HR+/HER2- early breast cancer

7 December 2022

Is the KI-67 level after neoadjuvant endocrine therapy associated with disease...